← All indications
Carcinoma, Transitional Cell
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
Drugs by status
Approved for this indication (4)
Phase 4 trials (9)
Phase 3 trials (53)
- cabazitaxel
- tislelizumab
- rogaratinib
- vinflunine
- epirubicin
- fluorouracil
- cobalamin
- valrubicin
- durvalumab
- cisplatin
- infigratinib
- eribulin
- ramucirumab
- utomilumab
- paclitaxel
- sacituzumab govitecan
- talazoparib
- epacadostat
- cabozantinib
- bt8009
- st-02
- n-dodecyl-b-d-maltoside
- panitumumab
- cmp-001
- 9mw2821
- shr-a2102
- ephb4-hsa fusion protein
- nivolumab
- ipilimumab
- toripalimab
- +23 more
Phase 2 trials (212)
- prolycopene
- pemigatinib
- spartalizumab
- abemaciclib
- aldesleukin
- aldoxorubicin
- zilovertamab vedotin
- dn24-02
- azd4547
- rifaximin
- mage-a1-specific t cell receptor-transduced autologous t-cells
- e-602
- nintedanib
- everolimus
- skb264
- F520
- erlotinib
- mln2480
- ivocizumab
- trastuzumab rezetecan
- ifosfamide
- etbx-051
- moxr0916
- vandetanib
- camrelizumab
- m1774
- oteracil
- gi-4000
- lurbinectedin
- sephb4-hsa
- +182 more
Phase 1 trials (136)
Organizations
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (62)
- Pierre Fabre
- Incyte
- Eisai
- Bristol-Myers Squibb
- Roche
- Immunomedics
- AstraZeneca
- Merck
- Eli Lilly
- Sanofi
- Bayer
- BeOne Medicines
- Endo Pharmaceuticals
- Cold Genesys, Inc.
- Shanghai Junshi Bioscience Co.,Ltd.
- Central European Cooperative Oncology Group
- Medical Research Council
- National Cancer Institute (NCI)
- University Hospital Birmingham NHS Foundation Trust
- Atlantic Health System
- Azienda Ospedaliera San Camillo Forlanini
- Baylor University
- Canadian Cancer Trials Group
- Cancer and Leukemia Group B (CALGB)
- University of London
- Harvard University
- Eastern Cooperative Oncology Group
- Gynecologic Oncology Group
- King Saud University
- NRG Oncology
- +32 more
Organization Involved with Phase 2 Indications (185)
- Cytogen
- Spectrum Pharmaceuticals
- Boston Biomedical
- Foundation Medicine
- Seattle Genetics
- Takeda
- Basilea Pharmaceutica
- Celgene
- Amgen
- Bausch Health Companies
- Clovis Oncology
- Genmab
- Astellas
- Genta
- Merck Serono
- Pharmacyclics
- Exelixis
- Genentech
- Pfizer
- AEterna Zentaris
- AIO-Studien-gGmbH
- Novartis
- Aprea Therapeutics AB
- BIND Therapeutics
- Dendreon
- Forty Seven, Inc.
- GlaxoSmithKline
- Hengrui Therapeutics, Inc.
- Infinity Pharmaceuticals, Inc.
- Inovio Pharmaceuticals
- +155 more
Organization Involved with Phase 1 Indications (44)
- Adaptimmune
- Daiichi Sankyo
- Advaxis, Inc.
- MedImmune
- Rainier Therapeutics
- Blue Earth Diagnostics
- Cell Genesys
- Corcept Therapeutics
- Merrimack Pharmaceuticals
- Oncolytics Biotech
- Vyriad, Inc.
- Apexigen, Inc.
- Principia Biopharma, Inc.
- University of Pittsburgh
- Augusta University
- Bnai Zion Medical Center
- Duke University
- Ludwig Institute for Cancer Research
- Rutgers University
- University of Iowa
- Columbia University
- University of Copenhagen
- University of Haifa
- University of Minnesota
- Neon Therapeutics
- Kyowa Kirin
- Hebrew University
- Five Prime Therapeutics
- Methodist Cancer Center, Houston, Texas
- Siddhi Vinayak Hospital
- +14 more
Organization Involved with Other Experimental Indications (7)